Kid ASA – Key information relating to payment of cash dividend
Source: Cision
The board approved a dividend of NOK 2.75 per share on 4 November 2026. The last day including the dividend right is 16 November, followed by an ex-date of 17 November and record date of 18 November; payment is scheduled for 27 November 2026.
Analysis
The announcement is a low-signal capital-return event without issuer identity, share price, earnings coverage, or dividend history. The NOK 2.75 payment cannot be translated into yield or assessed for sustainability; do not infer a recurring payout or improved fundamentals from this declaration alone. Near term, any price adjustment around the 17 November ex-date may largely reflect the dividend leaving the share price, rather than a durable change in value. The more important 1–3 month question is whether the payout is funded from recurring free cash flow or represents a one-off distribution; no evidence here resolves that. There is no basis to assess relative value, withholding treatment, or whether the amount is material to the issuer.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Key Decisions for Investors
- No directional trade on this disclosure alone. First identify the issuer and verify its share price, ordinary dividend policy, free-cash-flow coverage, balance-sheet position, and any accompanying guidance.
- For existing holders, confirm the broker’s entitlement cutoff and settlement treatment before the 16 November last day including right; avoid treating the ex-date price adjustment as a standalone bearish signal.
- Watch for issuer-specific confirmation of payout sustainability and any subsequent guidance or cash-flow disclosure. A payout funded by weaker liquidity or incremental borrowing would weaken the capital-return thesis; recurring cash-flow coverage would strengthen it.
More News
- Toyota hikes annual outlook and unveils $89 billion shareholder return plan
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Mizuho raises Cardinal Health stock price target on strong pharma growth
- TerrAscend narrows quarterly loss as revenue rises 4.8% on Pennsylvania growth
- Raymond James raises Targa Resources stock price target on Permian growth